Medical Radiology and Radiation Safety. 2022. Vol. 67. № 5

DOI: 10.33266/1024-6177-2022-67-5-52-58

L.I. Moskvicheva, S.V. Medvedev, L.V. Bolotina

POSSIBILITIES OF MODERN RADIATION THERAPY
IN PATIENTS WITH PANCREATIC CANCER

P.A. Hertsen Moscow Oncology Research Institute, Moscow, Russia

Contact person: Liudmila I. Moskvicheva, e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

ABSTRACT

Introduction: Until now, malignant neoplasms of the pancreas remain a very important oncological problem, which is determined by the long subclinical course of the disease, the primary diagnosis of most tumors already at advanced stages, as well as the pronounced effect of this pathology on the functional status and overall quality of life of patients. No more than a quarter of patients with pancreatic cancer can be operated on. The remaining significant part of patients receive palliative anticancer treatment and/or symptomatic therapy.

Purpose: The purpose of this work is to analyze the possibilities of modern methods of radiation therapy in patients with pancreatic cancer based on the analysis of scientific sources of the Internet resource National Center for Biotechnology Information.

Sections: This article describes the role of preoperative chemoradiotherapy using 3D-conformal techniques in patients with localized and borderline resectable pancreatic cancer, the effectiveness of chemoradiotherapy as an adjuvant component, and the possibilities of this method in patients with locally advanced disease. The advantages of modern radiotherapy regimens are demonstrated: with modulated intensity or volume intensity modulation by arches, stereotaxic technique, proton and adaptive MR-guided radiation therapy. The international experience of brachytherapy in patients with pancreatic cancer was analyzed.

Conclusion: Modern methods of radiotherapy are widely used in clinical practice for the treatment of patients with adenogenic pancreatic cancer. The implementation of various options for radiation or chemoradiation therapy can significantly increase the survival rates of patients with localized, borderline resectable and locally advanced process, the frequency of achieving local tumor control and its duration, as well as improve the quality of life of patients by reducing the severity of abdominal pain syndrome. Constant improvement in the technique of radiation treatment contributes to a natural decrease in the frequency of early and late radiation reactions.

Keywords: pancreatic cancer, radiation therapy, brachytherapy, proton beam therapy, intensity modulated radiation therapy, stereotactic body radiotherapy, adaptive magnetic resonance image-guided radiation therapy

For citation: Moskvicheva LI, Medvedev SV, Bolotina LV. Possibilities of Modern Radiation Therapy in Patients with Pancreatic Cancer. Medical Radiology and Radiation Safety. 2022;67(5):52–58. (In Russian). DOI: 10.33266/1024-6177-2022-67-5-52-58

 

References

1. Состояние онкологической помощи населению России в 2019 году / Под ред. Каприна А.Д., Старинского В.В., Шахзадовой А.О. М: МНИОИ им. П.А.Герцена, 2020. 239 с. [The State of Oncological Care to the Population of Russia in 2019. Ed. Kaprin A.D., Starinskiy V.V., Shakhzadova A.O. Moscow Publ., 2020. 239 p. (In Russ.)].

2. McGuigan A., Kelly P., Turkington R.C., Jones C., Coleman H.G., McCain R.S. Pancreatic Cancer: A Review of Clinical Diagnosis, Epidemiology, Treatment and Outcomes. World J. Gastroenterol. 2018;24;43:4846-4861. DOI: 10.3748/wjg.v24.i43.4846.

3. Москвичева Л.И., Петров Л.О., Сидоров Д.В. Возможности современных методов абляции при нерезектабельном местно-распространенном раке поджелудочной железы // Исследования и практика в медицине. 2018. Т.5, № 2 С. 86-99. [Moskvicheva L.I., Petrov L.O., Sidorov D.V. The Possibilities of Modern Methods of Ablation in Non-Resectable Locally Advanced Pancreatic Cancer. Issledovaniya i Praktika v Meditsine = Research’n Practical Medicine Journal. 2018;5;2:86-99 (In Russ.)]. DOI: 10.17709/2409-2231-2018-5-2-10.

4. Москвичева Л.И., Болотина Л.В. Возможности химиотерапии у больных местно-распространенным и метастатическим аденогенным раком поджелудочной железы // Исследования и практика в медицине. 2020. Т.7, № 4. С. 118-134. [Moskvicheva L.I., Bolotina L.V. Possibilities of Chemotherapy in Patients with Locally Advanced and Metastatic Adenogenic Pancreatic Cancer. Issledovaniya i Praktika v Meditsine = Research’n Practical Medicine Journal. 2020;7;4:118-134
(In Russ.)]. DOI: 10.17709/2409-2231-2020-7-4-10.

5. Robin T.P., Goodman K.A. Radiation Therapy in the Management of Pancreatic Adenocarcinoma: Review of Current Evidence and Future Opportunities. Chin. Clin. Oncol. 2017;6;3:28. DOI: 10.21037/cco.2017.06.12. 

6. Hong T.S., Ryan D.P., Borger D.R., Blaszkowsky L.S., Yeap B.Y., Ancukiewicz M., et al. A Phase 1/2 and Biomarker Study of Preoperative Short Course Chemoradiation with Proton Beam Therapy and Capecitabine Followed by Early Surgery for Resectable Pancreatic Ductal Adenocarcinoma. Int. J. Radiat. Oncol. Biol. Phys. 2014;89;4:830-838. DOI: 10.1016/j.ijrobp.2014.03.034.

7. Hall W.A., Goodman K.A. Radiation Therapy for Pancreatic Adenocarcinoma, a Treatment Option that must Be Considered in the Management of a Devastating Malignancy. Radiat. Oncol. 2019;14;1:114. DOI: 10.1186/s13014–019–1277–1.

8. Golcher H., Brunner T.B., Witzigmann H., Marti L., Bechstein W.O., Bruns C., et al. Neoadjuvant Chemoradiation Therapy with Gemcitabine/Cisplatin and Surgery Versus Immediate Surgery in Resectable Pancreatic Cancer: Results of the First Prospective Randomized Phase II Trial. Strahlenther Onkol. 2015;191;1:7-16. DOI: 10.1007/s00066–014–0737–7.

9. Versteijne E., Suker M., Groothuis K., Akkermans-Vogelaar J.M., Besselink M.G., Bonsing B.A., et al. Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial. J. Clin. Oncol. 2020;38;16:1763-1773. DOI: 10.1200/JCO.19.02274.

10. Hsu C.C., Herman J.M., Corsini M.M., Winter J.M., Callister M.D., Haddock M.G., et al. Adjuvant Chemoradiation for Pancreatic Adenocarcinoma: the Johns Hopkins Hospital-Mayo Clinic Collaborative Study. Ann. Surg. Oncol. 2010;17;4:981-990. DOI: 10.1245/s10434–009–0743–7.

11. Hammel P., Huguet F., van Laethem J.L., Goldstein D., Glimelius B., Artru P., et al. Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial. JAMA. 2016;315;17:1844-1853. DOI: 10.1001/jama.2016.4324.

12. Медведев С.В., Ткачев С.И. Рак поджелудочной железы // Терапевтическая радиология. Национальное руководство. Гл. 15 / Под ред. ак. Каприна А.Д., Мардынского Ю.С. М.: ГЭОТАР-Медиа, 2018. С. 155-159. [Medvedev S.V., Tkachev S.I. Pancreatic Cancer. Terapevticheskaya Radiologiya. Natsionalnoye Rukovodstvo = Therapeutic Radiology. National Leadership. Ch. 15. Ed. Kaprin A.D., Mardynskiy Yu.S. Moscow, GEOTAR-Media Publ., 2018. P. 155-159 (In Russ.)].

13. Krishnan S., Chadha A.S., Suh Y., Chen H.C., Rao A., Das P., et al. Focal Radiation Therapy Dose Escalation Improves Overall Survival in Locally Advanced Pancreatic Cancer Patients Receiving Induction Chemotherapy and Consolidative Chemoradiation. Int. J. Radiat. Oncol. Biol. Phys. 2016;94;4:755-765. DOI: 10.1016/j.ijrobp.2015.12.003.

14. Ткачев С.И., Медведев С.В., Знаткова Я.Р., Романов Д.С., и др. Возможности стереотаксической лучевой терапии при паллиативном лечении больных раком поджелудочной железы // Вопросы онкологии. 2015, Т.61, № 1. С. 121–124. [Tkachev S.I., Medvedev S.V., Znatkova Ya.R., Romanov D.S., et al. The Possibilities of Stereotactic Radiotherapy in Palliative Treatment of Patients with Pancreatic Cancer. Voprosy Onkologii = Problems in Oncology. 2015;61;1:121–124 (In Russ.)].

15. Reyngold M., Parikh P., Crane C.H. Ablative Radiation Therapy for Locally Advanced Pancreatic Cancer: Techniques and Results. Radiat. Oncol. 2019;14;1:95. DOI: 10.1186/s13014–019–1309–x.

16. Zhong J., Patel K., Switchenko J., Cassidy R.J., Hall W.A., Gillespie T., et al. Outcomes for Patients with Locally Advanced Pancreatic Adenocarcinoma Treated with Stereotactic Body Radiation Therapy Versus Conventionally Fractionated Radiation. Cancer. 2017;15;123;18:3486-3493. DOI: 10.1002/cncr.30706.

17. Dohopolski M.J., Glaser S.M., Vargo J.A., Balasubramani G.K., Beriwal S. Stereotactic Body Radiotherapy for Locally-Advanced Unresectable Pancreatic Cancer-Patterns of Care and Overall Survival. J. Gastrointest Oncol. 2017;8;5:766-777. DOI: 10.21037/jgo.2017.08.04.

18. Jung J., Yoon S.M., Park J.H., Seo D.W., Lee S.S., Kim M.H., et al. Stereotactic Body Radiation Therapy for Locally Advanced Pancreatic Cancer. PLoS One. 2019;14;4:e0214970. DOI: 10.1371/journal.pone.0214970.

19. Zhong J., Switchenko J., Behera M., Kooby D., Maithel S.K., McDonald M.W., et al. Chemotherapy with or Without Definitive Radiation Therapy in Inoperable Pancreatic Cancer. Ann Surg. Oncol. 2018;25;4:1026-1033. DOI: 10.1245/s10434–017–6322–4.

20. Herman J.M., Chang D.T., Goodman K.A., Dholakia A.S., Raman S.P., Hacker-Prietz A., et al. Phase 2 Multi-Institutional Trial Evaluating Gemcitabine and Stereotactic Body Radiotherapy for Patients with Locally Advanced Unresectable Pancreatic Adenocarcinoma. Cancer. 2015;121;7:1128-1137. DOI: 10.1002/cncr.29161.

21. Nichols R.C.Jr., George T.J., Zaiden R.A.Jr, Awad Z.T., Asbun H.J., Huh S., et al. Proton Therapy with Concomitant Capecitabine for Pancreatic and Ampullary Cancers is Associated with a Low Incidence of Gastrointestinal Toxicity. Acta. Oncol. 2013;52;3:498-505. DOI: 10.3109/0284186X.2012.762997.

22. Thompson R.F., Mayekar S.U., Zhai H., Both S., Apisarnthanarax S., Metz J.M., et al. A Dosimetric Comparison of Proton and Photon Therapy in Unresectable Cancers of the Head of Pancreas. Med. Phys. 2014;41;8:081711. DOI: 10.1118/1.4887797.

23. Hiroshima Y., Fukumitsu N., Saito T., Numajiri H., Murofushi K.N., Ohnishi K., et al. Concurrent Chemoradiotherapy Using Proton Beams for Unresectable Locally Advanced Pancreatic Cancer. Radiother Oncol. 2019;136:37-43. DOI: 10.1016/j.radonc.2019.03.012.

24. Henke L., Kashani R., Yang D., Zhao T., Green O., Olsen L., et al. Simulated Online Adaptive Magnetic Resonance-Guided Stereotactic Body Radiation Therapy for the Treatment of Oligometastatic Disease of the Abdomen and Central Thorax: Characterization of Potential Advantages. Int. J. Radiat. Oncol. Biol. Phys. 2016;96;5:1078-1086. DOI: 10.1016/j.ijrobp.2016.08.036.

25. Bohoudi O., Bruynzeel A.M.E., Senan S., Cuijpers J.P., Slotman B.J., Lagerwaard F.J., Palacios M.A. Fast and Robust Online Adaptive Planning in Stereotactic MR-Guided Adaptive Radiation Therapy (SMART) for Pancreatic Cancer. Radiother Oncol. 2017;125;3:439-444. DOI: 10.1016/j.radonc.2017.07.028.

26. Rudra S., Jiang N., Rosenberg S.A., Olsen J.R., Roach M.C., Wan L., et al. Using Adaptive Magnetic Resonance Image-Guided Radiation Therapy for Treatment of Inoperable Pancreatic Cancer. Cancer Med. 2019;8;5:2123-2132. DOI: 10.1002/cam4.2100.

27. Jia S.N., Wen F.X., Gong T.T., Li X., Wang H.J., Sun Y.M., Yang Z.C. A Review on the Efficacy and Safety of Iodine-125 Seed Implantation in Unresectable Pancreatic Cancers. Int. J. Radiat. Biol. 2020;96;3:383-389. DOI: 10.1080/09553002.2020.1704300. 

28. Sun X., Lu Z., Wu Y., Min M., Bi Y., Shen W., et al. An Endoscopic Ultrasonography-Guided Interstitial Brachytherapy Based Special Treatment-Planning System for Unresectable Pancreatic Cancer. Oncotarget. 2017;8;45:79099-79110. DOI: 10.18632/oncotarget.15763. 

29. Zhang K., Liao A., Jiang P., Jiang Y., Ji Z. Expert Consensus Workshop Report: Guideline for Three-Dimensional Printing Template-Assisted Computed Tomography-Guided 125i Seeds Interstitial Implantation Brachytherapy. J. Cancer Res. Ther. 2017;13;4:607-612. DOI: 10.4103/jcrt.JCRT_412_17.

30. Guo J.H., Hu X.K., Teng G.J. Radioactive Seed Implantation Therapy Technology: Problems and Development. Natl. Med. J. China. 2017;97:1444–1445.

31. Gai B., Zhang F. Chinese Expert Consensus on Radioactive 125I Seeds Interstitial Implantation Brachytherapy For Pancreatic Cancer. J. Cancer Res. Ther. 2018;14;7:1455-1462. DOI: 10.4103/jcrt.JCRT_96_18.

32. Folkert M.R., Gottumukkala S., Nguyen N.T., Taggar A., Sur R.K. Review of Brachytherapy Complications - Upper Gastrointestinal Tract. Brachytherapy. 2021;20;5:1005-1013. DOI: 10.1016/j.brachy.2020.11.010. 

33. Han Q., Deng M., Lv Y., Dai G. Survival of Patients with Advanced Pancreatic Cancer after Iodine125 Seeds Implantation Brachytherapy: A Meta-Analysis. Medicine (Baltimore). 2017;96;5:e5719. DOI: 10.1097/MD.0000000000005719. 

34. Chi Z., Chen L., Huang J., Jiang N., Zheng Q., Huang N., Yang W. A Novel Combination of Percutaneous Stenting with Iodine-125 Seed Implantation and Chemotherapy for the Treatment of Pancreatic Head Cancer with Obstructive Jaundice. Brachytherapy. 2021;20;1:218-225. DOI: 10.1016/j.brachy.2020.09.009.

35. Bhutani M.S., Cazacu I.M., Luzuriaga Chavez A.A., Singh B.S., Wong F.C.L., et al. Novel EUS-Guided Brachytherapy Treatment of Pancreatic Cancer with Phosphorus-32 Microparticles: First United States Experience. VideoGIE. 2019;4;5:223-225. DOI: 10.1016/j.vgie.2019.02.009.

 

 PDF (RUS) Full-text article (in Russian)

Conflict of interest. The authors declare no conflict of interest.

Financing. The study had no sponsorship.

Contribution. Article was prepared with equal participation of the authors.

Article received: 20.06.2022. Accepted for publication: 25.08.2022.